OVERVIEW
This free activity consists of a lecture presentation, a learning assessment, and an evaluation form.
The content of this virtual lecture is derived from a live education program presented on June 22, 2010, in
Hackensack, NJ.

MEDIUM: Virtual Lecture and Podcast
INTERNET RELEASE DATE: August 10, 2010
(Continuing education credit is no longer available for this activity.)

Estimated time to complete this activity: 2.0 hours

---

TARGET AUDIENCE
This activity has been designed to meet the educational needs of nurses, social workers and other healthcare professionals involved in the treatment of blood cancers.

---

ACTIVITY PURPOSE
To educate oncology nurses and social workers about advancing therapies for blood cancers.

---

STATEMENT OF NEED
Clinical trials test treatments for all stages of cancer. A clinical trial may be the best option for a newly diagnosed patient or for a patient whose cancer has relapsed. Participation in clinical trials by both men and women and by people of all ages and of different ethnic and cultural backgrounds is needed in order to continue to make progress in blood cancers. Oncology nurses and social workers have frequent contact with patients and as such are well-positioned to educate them about the potential benefits and risks of various treatment options.

---

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• List the steps patients need to take to understand their treatment options
• Explain ways to help patients become active participants in their care
• Define informed consent for participation in a clinical trial
• Describe the financial matters patients with blood cancers face

---

METHOD OF PARTICIPATION
To complete this activity and receive a statement of credit, participants must:

1. Review all contents of this activity
2. Complete and submit the learning assessment and evaluation form
3. Score at least 70% on the learning assessment

---

CONTINUING EDUCATION INFORMATION

NURSES AND SOCIAL WORKERS
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 2.0 continuing education contact hours through the California Board of Registered Nursing.

The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: 12/2008–12/2011. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 2.0 clinical clock hours.

---

FACULTY

Stuart L. Goldberg, MD
Chief, Division of Leukemia
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, NJ
Associate Clinical Professor of Medicine
University of Medicine & Dentistry of New Jersey
Newark, NJ

Gail J. Roboz, MD
Director, Leukemia Program
Associate Professor of Medicine
Weill Medical College of Cornell University
New York-Presbyterian Hospital
New York, NY

Maria Baldo, MS, PA-C
Senior Physician Assistant, Leukemia Service
Weill Medical College of Cornell University
New York-Presbyterian Hospital
New York, NY

John J. Hughes
MDS Survivor
Clinical Trial Participant
Bayonne, NJ

Louis J. DeGennaro, PhD
Executive Vice President and Chief Mission Officer
The Leukemia & Lymphoma Society
White Plains, NY

---

DISCLOSURE OF CONFLICTS OF INTEREST
All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to the activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. Faculty also are expected to disclose any unlabeled or investigational uses of products discussed in their presentations.

• Stuart L. Goldberg, MD, has asked that we advise participants in this activity that he has no affiliations at this time.
• Gail J. Roboz, MD, has asked that we advise participants in this activity that she has affiliations with Epicept, ChemGenex Pharmaceuticals, Cephalon, Celgene and Novartis.
• Maria Baldo, MS, PA-C, has asked that we advise participants in this activity that she has no affiliations at this time.
• John J. Hughes has asked that we advise participants in this activity that he has no affiliations at this time.
• Louis J. DeGennaro, PhD, has asked that we advise participants in this activity that he has no affiliations at this time.

---

STATEMENT OF SUPPORT
This program is supported by an educational grant from Genentech/Biogen Idec and an educational donation from Amgen.

---

FEE INFORMATION
There is no fee for this educational activity.

---

QUESTIONS AND TECHNICAL ASSISTANCE
For questions regarding the content of this activity, contact the Information Resource Center at 800-955-4572, or visit the LLS website at www.LLS.org. For technical assistance, contact jungsen@rmcom.net.

---

SYSTEM REQUIREMENTS
Hardware/Software requirements include:
• Windows 95, 98se, ME, XP, NT 4.0, 2000   
  - Internet Explorer 4.0+
  - Netscape Navigator 6.2+
  - Mozilla Firefox 1.0+
• Macintosh 9.2, OS X 10.1+
  - Safari 1.1+
  - Netscape Navigator 6.2+
  - Internet Explorer 5.2+
  - Mozilla Firefox 1.0+
• Additional Requirements
  - Windows Media Player
  - Internal/external speakers
  - Broadband connection (DSL/cable) recommended

 

 

RMEI Privacy Statement

Questions, grievances or assistance for people with disabilities, please contact the LLS Information Resource Center (IRC) at (800) 955-4572.